FDA Approves First Generic for Climara Pro Hormone Therapy Patch

The FDA has approved Zydus Pharmaceuticals’ estradiol and levonorgestrel transdermal system, the first generic of Bayer’s Climara Pro and a therapeutically equivalent, once-weekly combination hormone therapy patch for women with an intact uterus. Similar to its brand-name predecessor, the new formulation is approved for the treatment of moderate-to-severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis, according to a release.¹

“Menopause is a universal experience for women, and it can greatly affect a person’s quality of life,” said FDA Commissioner Kyle Diamantas, JD, according to the release. “Approvals like this reflect FDA’s ongoing commitment to expanding American patient access to safe, affordable, high-quality medications.”

Michael Davis, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research (CDER), emphasized that a once-weekly transdermal patch offers a convenient alternative to daily oral medications, which can significantly support patient adherence. Combining 0.045 mg of estradiol with 0.015 mg of levonorgestrel per day into a single application provides essential progestogen coverage to protect the endometrium while managing moderate-to-severe hot flashes and preserving bone density.^1,2

READ MORE: Study Links Oral Menopausal Hormone Therapy to Thrombotic Risk

Beyond routine symptom relief, however, expanding access to generic transdermal combination therapies addresses a systemic challenge in women's health.

Global health analyses from the World Economic Forum demonstrate that bridging essential health service gaps for women and girls builds broader community resilience and strengthens economic productivity. Furthermore, a White House executive order issued earlier this month highlights a federal priority to accelerate the research and clinical translation of stage-specific therapies for midlife and menopausal health conditions among women.^3,4

Clinical Applications and Strategic Value in Pharmacy Practice

For community and clinical pharmacists, the availability of a once-weekly generic patch represents an impactful tool in routine counseling and medication management. Although menopausal hormone therapy remains the gold standard for treating vasomotor symptoms, prescribing practices have evolved considerably toward lower effective estrogen doses and transdermal routes of administration.^5,6

Pharmacist Stephanie Young Moss, PharmD, MHSA, told Drug Topics that estrogen receptors exist throughout the body, meaning systemic hormone changes influence cardiometabolic wellness in addition to thermoregulation. By offering a lower-cost generic alternative to the brand-name Climara Pro, pharmacists can help patients maintain continuous therapy without financial disruption.^1,6

Pharmacists also play a vital role in identifying appropriate candidates while screening for critical contraindications and safety profiles.^1,5

Official labeling mandates that estradiol and levonorgestrel transdermal systems are contraindicated in women with undiagnosed genital bleeding, active or past breast cancer, hepatic impairment, active deep vein thrombosis or pulmonary embolism, and known thrombophilic disorders. Additionally, long-term transdermal hormone therapy requires careful monitoring for potential risks such as cardiovascular events or gallbladder disease.^1,2

Advancing Patient Education and Overcoming Historical Barriers

Despite clear therapeutic indications, widespread misconceptions surrounding hormone replacement therapy persist, tracing back to historic findings from the women's health initiative that led to steep declines in prescriptions. Modern clinical guidelines emphasize an individualized approach that weighs age, time since menopause onset, and administration route to determine the benefit-risk profile for each patient.^5,6

Pharmacists are uniquely positioned to address patient concerns, clarify the differences between commercial FDA-approved formulations and compounded bioidentical products, and emphasize proper administration techniques.^2,5

Proper patient education regarding patch application is essential to prevent site reactions and ensure therapeutic efficacy. Pharmacists should instruct patients to apply the patch once weekly to clean, dry, hair-free skin on the lower abdomen or upper buttocks, rotating application sites every week and avoiding the breasts or waistline.^1,2

As trusted accessible health care providers, pharmacists can leverage new generic approvals to expand clinical consultation, optimize medication adherence, and ensure women receive evidence-based care throughout the menopausal transition.^5,6

“In the US, 9 out of 10 prescriptions filled are for generic drugs,” concluded the FDA in its news release, which highlighted inclusion of this approval in its FDA Drug Competition Action Plan. “Increasing the availability of generic drugs helps to create competition in the marketplace, which then helps to make treatment more affordable and increases access to health care for more patients.”

READ MORE: Women’s Health Resource Center

REFERENCES

1. FDA approves once-weekly generic hormone therapy patch for women. FDA. News Release. October 20, 2026. Accessed October 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women?utm_medium=email&utm_source=govdelivery

2. Estradiol and levonorgestrel (transdermal route). Mayo Clinic. October 1, 2026. Accessed October 20, 2026. https://www.mayoclinic.org/drugs-supplements/estradiol-and-levonorgestrel-transdermal-route/description/drg-20112971

3. Access to healthcare: why we need to prioritize women and girls. World Economic Forum. May 28, 2022. Accessed October 20, 2026. https://www.weforum.org/stories/health-and-healthcare-systems/access-to-healthcare-prioritize-woman-and-girls

4. Advancing women’s health to improve outcomes in all phases of life. The White House. October 19, 2026. Accessed October 20, 2026. https://www.whitehouse.gov/presidential-actions/2026/10/advancing-womens-health-to-improve-outcomes-in-all-phases-of-life/

5. Cunningham J. A pharmacist’s guide to modern menopause management in 2026. Pharmacy Times. July 30, 2026. Accessed October 20, 2026. https://www.pharmacytimes.com/view/a-pharmacist-s-guide-to-modern-menopause-management-in-2026

6. Gallagher A, Moss SY, Albert E. How pharmacists can join the menopause care team. Drug Topics. October 7, 2026. Accessed October 20, 2026. https://www.drugtopics.com/view/how-pharmacists-can-join-the-menopause-care-team